rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
4
|
pubmed:dateCreated |
1998-12-31
|
pubmed:abstractText |
The incidence of acute rejection is considered to be higher after simultaneous pancreas-kidney (SPK) transplantation as compared to renal transplant alone. Therefore, the majority of SPK transplant recipients commonly receive a combination of cyclosporine (CsA) or tracolimus, and azathioprine or mycophenolic mofetyl, corticosteroids and/or antilymphocyte preparations. This study was designed to compare two immunosuppressive protocols for the prevention of acute rejection in patients undergoing SPK transplantation. The primary end-point was the incidence of acute rejection during the first 12 months after transplantation
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0085-2538
|
pubmed:author |
|
pubmed:issnType |
Print
|
pubmed:volume |
54
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1351-6
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:9767555-Adrenal Cortex Hormones,
pubmed-meshheading:9767555-Adult,
pubmed-meshheading:9767555-Animals,
pubmed-meshheading:9767555-Antilymphocyte Serum,
pubmed-meshheading:9767555-Azathioprine,
pubmed-meshheading:9767555-Cyclosporine,
pubmed-meshheading:9767555-Diabetes Mellitus, Type 1,
pubmed-meshheading:9767555-Diabetic Nephropathies,
pubmed-meshheading:9767555-Drug Therapy, Combination,
pubmed-meshheading:9767555-Female,
pubmed-meshheading:9767555-Graft Rejection,
pubmed-meshheading:9767555-Humans,
pubmed-meshheading:9767555-Immunosuppressive Agents,
pubmed-meshheading:9767555-Kidney Transplantation,
pubmed-meshheading:9767555-Male,
pubmed-meshheading:9767555-Middle Aged,
pubmed-meshheading:9767555-Pancreas Transplantation,
pubmed-meshheading:9767555-Prospective Studies,
pubmed-meshheading:9767555-Rabbits,
pubmed-meshheading:9767555-Safety
|
pubmed:year |
1998
|
pubmed:articleTitle |
Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation.
|
pubmed:affiliation |
Institut de Transplantation et de Recherche en Transplantation, Nantes University Hospital, France. dcantaro@sante.inserm.fr
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Randomized Controlled Trial
|